An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Moderate to severe rheumatoid arthritis , according to the revised ACR criteria * Patients initiated on RoActemra/Actemra treatment (in accordance with the local label) on their treating physicians decision Exclusion Criteria: * RoActemra/Actemra treatment more than 8 weeks prior to enrolment visit * Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use * Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra * History of autoimmune disease or of any joint inflammatory disease other than RA